ALKS 5461

an antidepressant that consists of samidorphan and buprenophrine

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Major Depressive Disorder (Major Depressive Disorders) 11/01/2018 - "A combination of buprenorphine (BUP) and samidorphan (SAM) at a 1:1 (mg/mg) fixed-ratio dose is being investigated as an adjunctive treatment of major depressive disorder (BUP/SAM, ALKS 5461). " 12/01/2019 - "Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). "
2.	Treatment-Resistant Depressive Disorder 01/01/2016 - "Considering the efficacy and safety of early off-label use of buprenorphine in the management of the treatment-resistant depression (TRD), it will be not surprising to predict the potential success of ALKS 5461 (a combination of buprenorphine and ALKS-33) in the near future. "

1.	Buprenorphine (Subutex)
2.	3-carboxamido-4-hydroxynaltrexone
3.	Antidepressive Agents (Antidepressants)
4.	Opioid Analgesics (Opioids)